(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Surface Oncology (SURF) has an average rating of buy and price targets ranging from $10 to $14, according to analysts polled by Capital IQ. (MT Newswires...
Surface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a...
Surface Oncology (SURF) said Thursday that it has received a $30 million milestone payment as GlaxoSmithKline (GSK) has dosed the first patient in a phase...
| Address | 50 Hampshire Street Cambridge, Massachusetts 02139 |
| Phone | +1.617.714.4096 |
| Number of Employees | 76 |
| Recent SEC Filing | 08/09/2022 SC 13G/A |
| President, Chief Executive Officer & Director | Robert W. Ross |
| Chief Financial Officer | Jessica Fees |
| Chief Scientific Officer | Vito J. Palombella |
| Chief Medical Officer | Alison M. O'Neill |
| Price Open | $1.76 |
| Previous Close | $1.73 |
| 52 Week Range | $1.37 - 8.38 |
| Market Capitalization | $100.4 M |
| Shares Outstanding | 58.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.30 |
| Beta vs. S&P 500 | N/A |
| Revenue | $59.4 M |
| Net Profit Margin | -206.10% |
| Return on Equity | -48.17% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
